Summary: GLP-1 receptor agonists can cause dizziness through mechanisms including hypoglycaemia, dehydration, orthostatic hypotension, and reduced caloric intake
The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence
It activates both GLP-1 and GIP receptors
Current areas of scientific investigation include tissue-associated signaling pathway analysis, extracellular matrix interaction studies, chondrocyte-related signaling investigations, cellular migration and organization research, multi-pathway signaling studies, and peptide interaction and pathway convergence investigations
Effects on maximum lifespan were determined by setting the threshold for lifespan to the 90th percentile for both groups combined 53
Botella-Estrada R, Kutzner H